Quince Therapeutics Announced Online Publication Of Data In Lancet Neurology From Its Phase 3 ATTeST Trial Of Its Lead Asset, Erydex (Dexamethasone Sodium Phosphate Encapsulated In Autologous Erythrocytes), For Ataxia-Telangiectasia
Quince Therapeutics Announced Online Publication Of Data In Lancet Neurology From Its Phase 3 ATTeST Trial Of Its Lead Asset, Erydex (Dexamethasone Sodium Phosphate Encapsulated In Autologous Erythrocytes), For Ataxia-Telangiectasia
Quince Therapeutics宣佈其主力資產Erydex（磷酸地塞米松封裝在自體紅細胞中）在小腦萎縮毛細血管擴張症(AT) 的3期ATTeSt試驗中數據在柳葉刀神經病學期刊上在線發表。
- Findings from largest completed study in A-T demonstrated favorable safety profile
- Study showed positive effect of EryDex treatment in a subset of patients with A-T ages six to nine – the age range that typically experiences rapid clinical decline
- Quince recently initiated pivotal Phase 3 NEAT study, which is currently enrolling and being conducted under U.S. FDA Special Protocol Assessment agreement
- 最大的A-t研究結果表明，安全性表現良好。
- 研究顯示，EryDex治療可對年齡在6至9歲之間的A-t患者的一個亞組產生積極效果——這個年齡區間通常會經歷急劇臨床惡化。
- Quince最近啓動了關鍵的第3階段NEAt研究，該研究目前正在招募患者並根據美國FDA特殊協議評估協議進行。
資訊熱榜
更新時間